From made-to-order genetic therapies to model organisms engineered to be ‘patient avatars’, the technology exists right now to save patients with rare diseases.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Kim, J. et al. N. Engl. J. Med. 381, 1644–1652 (2019).
Crooke, S. T. et al. Nat. Rev. Drug Discov. 20, 427–453 (2021).
Woodcock, J. & Marks, P. N. Engl. J. Med. 381, 1678–1680 (2019).
Brudvig, J. J. & Weimer, J. M. J. Clin. Invest. https://doi.org/10.1172/JCI157820 (2022).
Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Nat. Med. 28, 104–116 (2022).
Aartsma-Rus, A. et al. Nucleic Acid Ther. https://doi.org/10.1089/nat.2022.0060 (2022).
Schor, N. F., Tamiz, A. P., Koroshetz, W. J., NINDS Ultra-Rare Gene-based Therapy (URGenT) Working Group & Broome, A.-M. Nat. Biotechnol. 39, 1497–1499 (2021).
Urnov, F. New York Times https://www.nytimes.com/2022/12/09/opinion/crispr-gene-editing-cures.html (9 December 2022).
Rights and permissions
About this article
Cite this article
Seydel, C. Personalized medicine is having its day. Nat Biotechnol 41, 441–446 (2023). https://doi.org/10.1038/s41587-023-01724-9